Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - AVENUE THERAPEUTICS, INC. | tm2140561_ex31-1.htm |
| EX-32.2 - EXHIBIT 32.2 - AVENUE THERAPEUTICS, INC. | tm2140561_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - AVENUE THERAPEUTICS, INC. | tm2140561_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - AVENUE THERAPEUTICS, INC. | tm2140561_ex31-2.htm |
| EX-4.3 - EXHIBIT 4.3 - AVENUE THERAPEUTICS, INC. | tm2140561_ex4-3.htm |
| 10-K - FORM 10-K - AVENUE THERAPEUTICS, INC. | tm2140561_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Avenue Therapeutics, Inc.
New York, New York
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-224276) and Form S-8 (No. 333-219972) of Avenue Therapeutics, Inc. of our report dated March 31, 2021, relating to the financial statements which appears in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
New York, New York
March 31, 2021